Atreca, Inc. (BCEL)

Market Cap	10.26M
Revenue (ttm)	n/a
Net Income (ttm)	-84.60M
Shares Out	39.30M
EPS (ttm)	-2.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,096
Open	0.284
Previous Close	0.276
Day's Range	0.261 - 0.294
52-Week Range	0.255 - 2.050
Beta	1.05
Analysts	Hold
Price Target	3.38 (+1,195.02%)
Earnings Date	Nov 9, 2023

About BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 90
• Stock Exchange: NASDAQ
• Ticker Symbol: BCEL

Analyst Forecast

According to 5 analysts, the average rating for BCEL stock is "Hold." The 12-month stock price forecast is $3.38, which is an increase of 1,195.02% from the latest price.

Price Target

$3.38

(1,195.02% upside)

Analyst Consensus: Hold